Bristol Myers Squibb (BMY) Free Cash Flow (2009 - 2026)
Bristol Myers Squibb (BMY) reported Free Cash Flow of $757.0 million for Q1 2026, down 55.31% year-over-year from $1.7 billion in Q1 2025, and down 52.81% on a QoQ basis from $1.6 billion in Q4 2025.
Bristol Myers Squibb (BMY) has 18 years of Free Cash Flow data on file, last reported at $757.0 million in Q1 2026.
- Quarterly Free Cash Flow fell 55.31% year-over-year to $757.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.9 billion (down 9.0% YoY) and the FY2025 annual result came in at $12.8 billion, down 7.87% from the prior year.
- Free Cash Flow retreated to $757.0 million in Q1 2026 per BMY's latest filing, from $1.6 billion in the prior quarter.
- Across five years, Free Cash Flow topped out at $6.0 billion in Q3 2025 and bottomed at $757.0 million in Q1 2026.
- The 5-year median for Free Cash Flow is $3.0 billion (2022), against an average of $3.1 billion.
- Peak annual rise in Free Cash Flow reached 72.29% in 2025, while the deepest fall reached 60.5% in 2025.
- Tracing BMY's Free Cash Flow over 5 years: stood at $3.0 billion in 2022, then surged by 32.5% to $3.9 billion in 2023, then increased by 3.54% to $4.1 billion in 2024, then sank by 60.5% to $1.6 billion in 2025, then plunged by 52.81% to $757.0 million in 2026.
- Per Business Quant, the three latest BMY Free Cash Flow figures stand at $757.0 million (Q1 2026), $1.6 billion (Q4 2025), and $6.0 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 346.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.01 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 1.47 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 3.56 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 2.93 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.48 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.43 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.18 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 757.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 757.00 Mn |
| Mar 31, 2026 | 757.00 Mn |
| Dec 31, 2025 | 1.60 Bn |
| Dec 31, 2025 | 1.60 Bn |
| Sep 30, 2025 | 5.99 Bn |
| Sep 30, 2025 | 5.99 Bn |
| Jun 30, 2025 | 3.56 Bn |
| Jun 30, 2025 | 3.56 Bn |
| Mar 31, 2025 | 1.69 Bn |
| Mar 31, 2025 | 1.69 Bn |
| Dec 31, 2024 | 4.06 Bn |
| Dec 31, 2024 | 4.06 Bn |
| Sep 30, 2024 | 5.27 Bn |
| Sep 30, 2024 | 5.27 Bn |
| Jun 30, 2024 | 2.06 Bn |
| Jun 30, 2024 | 2.06 Bn |
| Mar 31, 2024 | 2.55 Bn |
| Mar 31, 2024 | 2.55 Bn |
| Dec 31, 2023 | 3.92 Bn |
| Dec 31, 2023 | 3.92 Bn |
| Sep 30, 2023 | 4.41 Bn |
| Sep 30, 2023 | 4.41 Bn |
| Jun 30, 2023 | 1.63 Bn |
| Jun 30, 2023 | 1.63 Bn |
| Mar 31, 2023 | 2.69 Bn |
| Mar 31, 2023 | 2.69 Bn |
| Dec 31, 2022 | 2.96 Bn |
| Dec 31, 2022 | 2.96 Bn |
| Sep 30, 2022 | 3.44 Bn |
| Sep 30, 2022 | 3.44 Bn |
| Jun 30, 2022 | 1.99 Bn |
| Jun 30, 2022 | 1.99 Bn |
| Mar 31, 2022 | 3.56 Bn |
| Mar 31, 2022 | 3.56 Bn |
| Dec 31, 2021 | 3.74 Bn |
| Dec 31, 2021 | 3.74 Bn |
| Sep 30, 2021 | 5.00 Bn |
| Sep 30, 2021 | 5.00 Bn |
| Jun 30, 2021 | 2.85 Bn |
| Jun 30, 2021 | 2.85 Bn |
| Mar 31, 2021 | 3.65 Bn |
| Mar 31, 2021 | 3.65 Bn |
| Dec 31, 2020 | 3.07 Bn |
| Dec 31, 2020 | 3.07 Bn |
| Sep 30, 2020 | 2.11 Bn |
| Sep 30, 2020 | 2.11 Bn |
| Jun 30, 2020 | 4.36 Bn |
| Jun 30, 2020 | 4.36 Bn |
| Mar 31, 2020 | 3.75 Bn |
| Mar 31, 2020 | 3.75 Bn |
| Dec 31, 2019 | 1.93 Bn |
| Dec 31, 2019 | 1.93 Bn |
| Sep 30, 2019 | 2.37 Bn |
| Sep 30, 2019 | 2.37 Bn |
| Jun 30, 2019 | 1.89 Bn |
| Jun 30, 2019 | 1.89 Bn |
| Mar 31, 2019 | 1.19 Bn |
| Mar 31, 2019 | 1.19 Bn |
| Dec 31, 2018 | 3.27 Bn |
| Dec 31, 2018 | 3.27 Bn |
| Sep 30, 2018 | 1.06 Bn |
| Sep 30, 2018 | 1.06 Bn |
| Jun 30, 2018 | 859.00 Mn |
| Jun 30, 2018 | 859.00 Mn |
| Mar 31, 2018 | 936.00 Mn |
| Mar 31, 2018 | 936.00 Mn |
| Dec 31, 2017 | 863.00 Mn |
| Dec 31, 2017 | 863.00 Mn |
| Sep 30, 2017 | 1.45 Bn |
| Sep 30, 2017 | 1.45 Bn |
| Jun 30, 2017 | 1.34 Bn |
| Jun 30, 2017 | 1.34 Bn |
| Mar 31, 2017 | 570.00 Mn |
| Mar 31, 2017 | 570.00 Mn |
| Dec 31, 2016 | 1.07 Bn |
| Dec 31, 2016 | 1.07 Bn |
| Sep 30, 2016 | 1.06 Bn |
| Sep 30, 2016 | 1.06 Bn |
| Jun 30, 2016 | 178.00 Mn |
| Jun 30, 2016 | 178.00 Mn |
| Mar 31, 2016 | -470.00 Mn |
| Mar 31, 2016 | -470.00 Mn |
| Dec 31, 2015 | 599.00 Mn |
| Dec 31, 2015 | 599.00 Mn |
| Sep 30, 2015 | 290.00 Mn |
| Sep 30, 2015 | 290.00 Mn |
| Jun 30, 2015 | -94.00 Mn |
| Jun 30, 2015 | -94.00 Mn |
| Mar 31, 2015 | 490.00 Mn |
| Mar 31, 2015 | 490.00 Mn |
| Dec 31, 2014 | 381.00 Mn |
| Dec 31, 2014 | 381.00 Mn |
| Sep 30, 2014 | 796.00 Mn |
| Sep 30, 2014 | 796.00 Mn |
| Jun 30, 2014 | 946.00 Mn |
| Jun 30, 2014 | 946.00 Mn |
| Mar 31, 2014 | 499.00 Mn |
| Mar 31, 2014 | 499.00 Mn |
| Dec 31, 2013 | 1.21 Bn |
| Dec 31, 2013 | 1.21 Bn |
| Sep 30, 2013 | 929.00 Mn |
| Sep 30, 2013 | 929.00 Mn |
| Jun 30, 2013 | 1.41 Bn |
| Jun 30, 2013 | 1.41 Bn |
| Mar 31, 2013 | -543.00 Mn |
| Mar 31, 2013 | -543.00 Mn |
| Dec 31, 2012 | 661.00 Mn |
| Dec 31, 2012 | 661.00 Mn |
| Sep 30, 2012 | 4.45 Bn |
| Sep 30, 2012 | 4.45 Bn |
| Jun 30, 2012 | 1.02 Bn |
| Jun 30, 2012 | 1.02 Bn |
| Mar 31, 2012 | 264.00 Mn |
| Mar 31, 2012 | 264.00 Mn |
| Dec 31, 2011 | 1.43 Bn |
| Dec 31, 2011 | 1.43 Bn |
| Sep 30, 2011 | 1.61 Bn |
| Sep 30, 2011 | 1.61 Bn |
| Jun 30, 2011 | 1.02 Bn |
| Jun 30, 2011 | 1.02 Bn |
| Mar 31, 2011 | 406.00 Mn |
| Mar 31, 2011 | 406.00 Mn |
| Dec 31, 2010 | 1.47 Bn |
| Dec 31, 2010 | 1.47 Bn |
| Sep 30, 2010 | 1.29 Bn |
| Sep 30, 2010 | 1.29 Bn |
| Jun 30, 2010 | 968.00 Mn |
| Jun 30, 2010 | 968.00 Mn |
| Mar 31, 2010 | 335.00 Mn |
| Mar 31, 2010 | 335.00 Mn |
| Dec 31, 2009 | 1.15 Bn |
| Dec 31, 2009 | 1.15 Bn |
| Sep 30, 2009 | 1.30 Bn |
| Sep 30, 2009 | 1.30 Bn |